IL2 and renal cell adenocarcinoma: Recombinant human IL-2 (Proleukin, aldesleukin) was approved by the United States Food and Drug Administration for metastatic melanoma and renal cell cancer [6]; however, adverse events associated with high-dose IL-2, including capillary leak syndrome (VLS), limit its therapeutic use [7,8,9].